Initial Evaluation of [<sup>18</sup>F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Watabe, Tadashi; Naka, Sadahiro; Tatsumi, Mitsuaki; Kamiya, Takashi; Kimura, Tōru; Shintani, Yasushi; Abe, Kaori; Miyake, Tomohiro; Shimazu, Kenzo; Kobayashi, Shogo; Kurokawa, Yukinori; Eguchi, Hidetoshi; Doki, Yuichiro; Inohara, Hidenori; Kato, Hirohisa; Mori, Yuriko; Cardinale, Jens; Giesel, Frederik L.

doi:10.2967/jnumed.123.265486

Cited by 16 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advance of novel diagnostic PSMA (Fendler et al 2023) and fibroblast activation inhibitor-ligands (Watabe et al 2023) has great potential for expanding the range of pre-therapeutic dosimetry far beyond the context of differentiated thyroid cancer, where iodine-124 is used in individualized treatment strategies (Weber et al 2019). For example, Peters et al (2022) studied the feasibility of gallium-68-PSMA-PET/CT-based lesion dosimetry prior to lutetium-177-PSMA radionuclide therapy in the context of prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

PET quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning

Hammersen,

Jentzen,

Stawitzki

et al. 2024

Phys. Med. Biol.

View full text Add to dashboard Cite

Objective: The partial-volume effect (PVE) is an important factor impairing tumour quantification in molecular imaging. The commonly used contour-volume-of-interest (contour-VOI) approach to correct for this effect employs phantom-based recovery coefficients. Applying oversize-VOIs could offer superior quantification accuracy in small lesions. The oversize-VOI approach uses a large oversize volume to determine the total tumour activity after applying a background correction. Aims of this study were to provide a procedure for the application of an oversize-VOI approach and to compare its performance to the contour-VOI approach in PET imaging. Approach: A sphere tumour model was simulated to determine the oversize diameter that contained 90%, 95%, and 98% of the total activity as a function of the tumour size. Experimental investigations involving phantom and clinical data were conducted on a digital PET/CT scanner. In the phantom investigation, 12 spherical tumour inserts (diameters ranging from 3.7 to 37.4 mm) containing 18F-solution were used. The accuracy of the contour- and oversize-VOI approach was evaluated for different signal-to-background ratios (20 to 3). Clinically, both approaches were applied on PET/CT images acquired with 18F-labelled prostate-specific membrane antigen in prostate cancer patients. Main results: From the tumour model, we deduced that an oversize-VOI of two PET spatial resolutions larger than the physical lesion diameter contains at least 98% of the total activity for lesions with diameters down to one PET spatial resolution, while minimizing the background contribution. Both approaches were robust against varying phantom and clinical imaging conditions. Performance of the oversize-VOI approach was favorable for lesions below 10 mm in diameter, whereas the contour-VOI approach was slightly more accurate for sizes above 10 mm. Significance: The oversize-VOI approach facilitates image quantification of small tumours. It is simple and effective to correct for the PVE, and may be used in pre-therapeutic (small) tumour dosimetry.

show abstract

Section: Discussionmentioning

confidence: 99%

PET quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning

Hammersen,

Jentzen,

Stawitzki

et al. 2024

Phys. Med. Biol.

View full text Add to dashboard Cite

show abstract

“…At was produced via the nuclear reaction of 209 Bi(a, 2n) 211 At using azimuthally varying field cyclotrons (Research Center for Nuclear Physics, Osaka University, and Radioactive Isotope Beam Factory, Institute of Physical and Chemical Research) and purified using a dry distillation method (17). The isolated 211 At was introduced into previously prepared [B] 10 -GPC1 mAbs (clone 01a033 or clone [1][2][3][4][5][6][7][8][9][10][11][12]. The synthesis of [B] 10 -GPC1 mAb is described in the supplemental materials (supplemental materials are available at http://jnm.snmjournals.org).…”

Section: Synthesis Of [ 211 At]gpc1 Mab 211mentioning

confidence: 99%

“…Detection of PDAC is sometimes difficult because abnormalities are not shown in CT images for small tumors (2). In addition, some PDACs are not [ 18 F]FDG-avid and cannot be detected using conventional [ 18 F]FDG PET (3). Therefore, new precise imaging techniques for the early detection of PDAC, as well as the development of new therapies in combination with theranostic approaches, are needed.…”

mentioning

confidence: 99%

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with⁸⁹Zr or²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma

Watabe,

Kabayama,

Naka

et al. 2023

J Nucl Med

Self Cite

View full text Add to dashboard Cite

“…Compared to 68 [Ga]Ga-FAPI, [ 18 F]FAPI exhibit similar characteristics, biodistribution and tracer kinetics, such as high affinity to tumor, swift renal clearance and minimal non-specific uptake in normal tissue (Hu et al 2022 ). That made that [ 18 F]FAPI has performed promising diagnostic performance for various cancers (Yang et al 2023 ; Zhang et al 2023 ; Watabe et al 2023 ; Yao et al 2022 ). However, a distinction between 68 Ga- and 18 F-FAPI lies in the chelator (normally DOTA for 68 [Ga]Ga-FAPI; NOTA for [ 18 F]FAPI).…”

Section: Introductionmentioning

confidence: 99%

Comparative analysis of two timepoints on [18F]FAPI-42 PET/CT in various cancers

Mu,

Mo,

Qin

et al. 2023

European J Hybrid Imaging

View full text Add to dashboard Cite

Purpose This study aimed to assess the biodistribution, detection rate, and uptake of the [18F]FAPI-42 at two distinct time intervals. Methods This prospective study enrolled 60 consecutive patients (median age 59; range 35–74) referred to [18F]FAPI-42 PET/CT. [18F]FAPI-42 PET/CT was performed early and late timepoint after tracer injection for staging or restaging. Positive lesions specified for anatomic locations (primary or recurrent tumor, LN metastasis and other metastasis) by visual analysis at both timepoints. Semiquantitative analysis of the tracer activity in lesions as well as normal tissues at both time points were measured and compared. In a subgroup analysis, eleven patients underwent 2-[18F]FDG PET/CT within 1 week, the detection rate and uptake of lesion were compared between early [18F]FAPI-42 and 2-[18F]FDG. Results Uptake of [18F]FAPI-42 in the late timepoint was significantly lower than the early timepoint in most organs (all p < 0.05), except for bone (SUVmean 0.88 vs. 0.85; p = 0.218). Tracer retention at biliary system showed less frequent at early timepoint than late timepoint. A total of 194 lesions were detected in 60 patients. One lesion was only seen at early timepoint but not at late timepoint. Lesions on early [18F]FAPI-42 PET/CT had higher visual score than that of late image(23 vs. 6). The uptake of lesion decreased significantly from early to late timepoint (all p < 0.05). In subgroup analysis, early [18F]FAPI-42 illustrated higher detection rate, visual score, and uptake of lesion than that of 2-[18F]FDG PET/CT. Conclusion Early [18F]FAPI-42 PET/CT provided consistent detection rates and lesion uptake, but less tracer retention in the biliary system compared to late images. Therefore, acquisition at early timepoint could be a feasible strategy for improving acquisition protocols of [18F]FAPI-42 PET/CT. Trial registration: ChiCTR2200063441. Registered 28 September 2022—Retrospectively registered, https://www.chictr.org.cn/bin/project/edit?pid=149714.

show abstract

Initial Evaluation of [¹⁸F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Cited by 16 publications

References 23 publications

PET quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning

PET quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with⁸⁹Zr or²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma

Comparative analysis of two timepoints on [18F]FAPI-42 PET/CT in various cancers

Contact Info

Product

Resources

About

Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Cited by 16 publications

References 23 publications

PET quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning

PET quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with89Zr or211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma

Comparative analysis of two timepoints on [18F]FAPI-42 PET/CT in various cancers

Contact Info

Product

Resources

About

Initial Evaluation of [¹⁸F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with⁸⁹Zr or²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma